June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Chromosome 6p amplification detected in blood cell-free DNA in advanced retinoblastoma
Author Affiliations & Notes
  • Shreya Sirivolu
    The Vision Center, Children's Hospital of Los Angeles, Los Angeles, California, United States
    Roski Eye Institute, University of Southern California Keck School of Medicine, Los Angeles, California, United States
  • Liya Xu
    The Vision Center, Children's Hospital of Los Angeles, Los Angeles, California, United States
    Roski Eye Institute, University of Southern California Keck School of Medicine, Los Angeles, California, United States
  • Peter Kuhn
    Department of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, California, United States
    Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California, United States
  • James Hicks
    Department of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, California, United States
    Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California, United States
  • Jesse L Berry
    The Vision Center, Children's Hospital of Los Angeles, Los Angeles, California, United States
    Roski Eye Institute, University of Southern California Keck School of Medicine, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Shreya Sirivolu None; Liya Xu Aqueous Humor Cell Free DNA for Diagnostic and Prognostic Evaluation of Ophthalmic Disease, Code P (Patent); Peter Kuhn None; James Hicks Aqueous Humor Cell Free DNA for Diagnostic and Prognostic Evaluation of Ophthalmic Disease, Code P (Patent); Jesse Berry Aqueous Humor Cell Free DNA for Diagnostic and Prognostic Evaluation of Ophthalmic Disease, Code P (Patent)
  • Footnotes
    Support  Wright Foundation, National Cancer Institute of the National Institute of Health Award K08CA232344, National Institute of Health P30EY029220, National Cancer Institute P30CA014089, Hyundai Hope on Wheels RGA012351, American Cancer Society IRG-16-181-57, Knights Templar Eye Foundation, Institute for Families, Inc., Children’s Hospital Los Angeles, Larry and Celia Moh Foundation, Nautica Foundation, Research to Prevent Blindness, an unrestricted departmental grant, USC Dornsife College of Letters, Arts and Sciences, Vicky Joseph Research Fund, Carol Vassiliadis Research Fund
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2332 – A0001. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shreya Sirivolu, Liya Xu, Peter Kuhn, James Hicks, Jesse L Berry; Chromosome 6p amplification detected in blood cell-free DNA in advanced retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2332 – A0001.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Both aqueous humor (AH) and blood-based liquid biopsies can carry tumor-derived cell-free DNA (cfDNA) in retinoblastoma (RB) patients. Detection of somatic copy number alterations (SCNAs) requires approximately 5% tumor fraction, as such have only previously been detected in AH, which is an enriched source of tumor DNA. We analyzed AH and blood cfDNA taken at the time of primary enucleation to compare SCNA profiles and somatic RB1 mutation detection between both biospecimens.

Methods : One patient diagnosed with advanced unilateral RB (Group D/AJCC Stage cT2B) was included. After isolating cfDNA from AH and blood, constructed whole genome libraries were sequenced on an Illumina platform to assess genome-wide SCNAs, which were considered positive at 20% deflection from the baseline. Correlation between SCNA profiles was calculated using Pearson correlation coefficient. The libraries were also used to identify somatic RB1 pathogenic variants using a comprehensive cancer panel that includes all RB1 exons.

Results : In the peripheral blood, a germline RB1 mutation was not detected, however a heterozygous mutation (c.3920T>A) in the APC gene was reported from clinical testing. Genomic analysis of the tumor revealed two somatic RB1 mutations that were not present in germline, c.1589_1590del with a variant allele frequency (VAF) of 84.0% and c.2330dupC with VAF of 40.0%. These mutations were similarly detected in the AH, with VAFs of 78.9% and 45.27% respectively, but were not detected in the blood. Genomic analysis of both tumor and AH demonstrated highly recurrent RB SCNAs such as gains on 1q, 2p, and 6p, in addition to other alterations. The AH SCNA profile was highly concordant with the tumor profile (r=0.987; p<0.0001). 6p gain was detected in the blood and comparison of the 6p amplitude between AH and blood suggests approximately 12% tumor fraction in the blood.

Conclusions : To our knowledge, this is the first time an SCNA has been detected in the blood of an RB patient, suggesting a high enough tumor fraction. No metastasis has been identified, however monitoring is ongoing. The results illustrate the benefits and limitations of both AH and blood-based liquid biopsies. While AH is composed of more highly enriched eye-specific tumor information, only blood can provide information regarding systemic disease and metastasis.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

SCNA profiles comparing (A) AH and tumor and (B) blood and tumor.

SCNA profiles comparing (A) AH and tumor and (B) blood and tumor.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×